Bridging the Gap: The First Pan-Canadian Consensus on Acute Radiation Dermatitis (ARD) Management in Breast Cancer

Bridging the Gap: The First Pan-Canadian Consensus on Acute Radiation Dermatitis (ARD) Management in Breast Cancer

Infographic

Did you know: 90% of breast cancer patients receiving radiation therapy develop radiodermatitis (ARD). This pervasive complication significantly impacts patient quality of life and risks treatment interruption.
This essential infographic summarizes the Pan-Canadian Modified Delphi Consensus developed by a panel of 19 leading experts across Radiation Oncology, Onco-Dermatology, Dermatology, and Nursing.

What You Will Learn:

  • Standardized Care:
    Navigate the complexity of ARD with the first-ever Canadian evidence-based guidelines.
  • Expert Consensus:
    Apply the collective knowledge of top specialists to your daily practice.
  • Optimize Outcomes:
     Identify and apply proven interventions for the prevention and management of ARD.

Download the Infographic to transform your clinical decision-making and enhance patient care strategies.

Supported by unrestricted educational funding from La Roche-Posay.